Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03607422 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 912
- Enrollment target
NCT03607422 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 912 participants.
The verdict
NCT03607422, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 912 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Interventions
- DRUG Upadacitinib
- DRUG Placebo for Upadacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 912 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2025-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03607422
The ClinicalTrials.gov registry entry for NCT03607422 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 912 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upadacitinib is the first listed.
NCT03607422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03607422 about?
NCT03607422 is a clinical study titled "A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)". The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT03607422?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 912 participants. The study started on 2018-07-27. Estimated completion is 2025-11-11.
What interventions are being tested in trial NCT03607422?
The interventions under investigation include: Upadacitinib (DRUG), Placebo for Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT03607422?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.